Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immatics ( (IMTX) ) has shared an announcement.
On March 5, 2026, Immatics reported its full-year 2025 results and outlined progress across its PRAME-franchise programs, led by anzu-cel, which is in the global Phase 3 SUPRAME trial for previously treated advanced cutaneous melanoma and holds U.S. Orphan Drug and RMAT designations in cutaneous and uveal melanoma. The company confirmed timelines for interim and final SUPRAME analyses in 2026, a planned BLA filing in the first half of 2027 and a potential commercial launch in the second half of 2027, supported by ongoing Phase 1/2 melanoma studies, a Moderna-backed combination trial, advancing next-generation IMA203CD8 and IMA402 bispecific programs, and a strengthened balance sheet with $551.4 million in cash and equivalents after a $125 million offering, extending its cash runway into 2028.
Immatics also highlighted positive early data for IMA203CD8 in PRAME-positive tumors, including ovarian cancer, and laid out 2026 data catalysts for this second-generation cell therapy and for its IMA402 PRAME bispecific, which is moving toward indication-specific expansion cohorts and a planned combination trial with IMA401 in squamous non-small cell lung cancer. Taken together, the clinical momentum, regulatory designations and extended funding horizon reinforce Immatics’ bid to establish a first-to-market position in PRAME-targeted therapies while broadening its addressable patient population in solid tumors.
The most recent analyst rating on (IMTX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ overall stock score is primarily influenced by its financial performance challenges, including inconsistent revenue growth and profitability. Positive technical indicators provide some support, suggesting potential short-term bullish momentum. However, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a clinical-stage biopharmaceutical company based in Germany and the U.S., specializing in T cell–based immunotherapies that precisely target the cancer antigen PRAME. Its pipeline includes autologous cell therapies and bispecific biologics for solid tumors, with an initial commercial focus on advanced melanoma and expansion into gynecologic and other PRAME-positive cancers.
Average Trading Volume: 409,334
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.32B
For detailed information about IMTX stock, go to TipRanks’ Stock Analysis page.